Australia · Delayed Price · Currency is AUD Zelira Therapeutics Company Description
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States.
It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia.
The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology.
In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019.
Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
| Country | Australia |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Oludare Odumosu |
Contact Details
Address: 101 St Georges Terrace Perth, 6000 Australia | |
| Phone | 61 8 6558 0886 |
| Website | zeliratx.com |
Stock Details
| Ticker Symbol | ZLD |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000ZLD1 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oludare Odumosu | MD, Global Chief Executive Officer and Director |
| Osagie O. Imasogie Esq. | Founder and Chairman |
| Greg Blake | Executive Director |
| Timothy Ryan Slate | Company Secretary and Non-Executive Director |
| Rahul Ganesan | Vice President of Finance and Accounting |
| Dr. Patty Washer | Clinical Trial Consultant |